News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
606,753 Results
Type
Article (36921)
Company Profile (131)
Press Release (569701)
Section
Business (172582)
Career Advice (2735)
Deals (32377)
Drug Delivery (78)
Drug Development (72610)
Employer Resources (156)
FDA (15566)
Job Trends (14558)
News (300138)
Policy (29050)
Tag
Academia (2651)
Alliances (43027)
Alzheimer's disease (1256)
Approvals (15492)
Artificial intelligence (114)
Bankruptcy (280)
Best Places to Work (11964)
Biotechnology (96)
Breast cancer (110)
Cancer (924)
Career advice (2267)
Cell therapy (214)
Clinical research (57465)
Collaboration (330)
Compensation (170)
COVID-19 (2470)
C-suite (89)
Cystic fibrosis (79)
Data (919)
Diabetes (135)
Diagnostics (6359)
Earnings (65988)
Employer resources (137)
Events (98855)
Executive appointments (267)
FDA (16025)
Funding (293)
Gene therapy (152)
GLP-1 (493)
Government (4015)
Healthcare (19691)
Infectious disease (2544)
Inflammatory bowel disease (106)
Interviews (537)
IPO (15934)
Job creations (2923)
Job search strategy (1892)
Layoffs (375)
Legal (6409)
Lung cancer (152)
Manufacturing (150)
Medical device (13770)
Medtech (13775)
Mergers & acquisitions (16557)
Metabolic disorders (321)
Neuroscience (1495)
NextGen Class of 2024 (6709)
Non-profit (4811)
Northern California (1282)
Obesity (171)
Opinion (202)
Patents (98)
People (50612)
Phase I (17796)
Phase II (25468)
Phase III (19161)
Pipeline (248)
Postmarket research (2047)
Preclinical (7280)
Radiopharmaceuticals (249)
Rare diseases (195)
Real estate (4904)
Regulatory (19796)
Research institute (2435)
Resumes & cover letters (448)
Southern California (1156)
Startups (3036)
United States (12180)
Vaccines (502)
Weight loss (116)
Date
Today (215)
Last 7 days (938)
Last 30 days (3269)
Last 365 days (36468)
2024 (31617)
2023 (41362)
2022 (52232)
2021 (57143)
2020 (55648)
2019 (48778)
2018 (36683)
2017 (32197)
2016 (30464)
2015 (35549)
2014 (24805)
2013 (19331)
2012 (20850)
2011 (21634)
2010 (18715)
Location
Africa (762)
Arizona (113)
Asia (35518)
Australia (6322)
California (2850)
Canada (1189)
China (208)
Colorado (129)
Connecticut (131)
Europe (82324)
Florida (414)
Georgia (111)
Illinois (312)
Indiana (187)
Kansas (93)
Maryland (523)
Massachusetts (2391)
Michigan (160)
Minnesota (253)
New Jersey (853)
New York (859)
North Carolina (723)
Northern California (1282)
Ohio (133)
Pennsylvania (775)
South America (1087)
Southern California (1156)
Texas (399)
Utah (87)
Washington State (332)
606,753 Results for "astrazeneca ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” to AstraZeneca, but contends that the share selloff is “overdone” and likely a knee-jerk reaction by investors.
November 6, 2024
·
2 min read
·
Tristan Manalac
Obesity
AstraZeneca Bolsters Obesity Pipeline With Promising Early Data for Candidates
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb studies and creates a “foothold” for AstraZeneca in the weight loss space.
November 5, 2024
·
3 min read
·
Tristan Manalac
People
From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca
Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always been a priority for the AstraZeneca executive.
October 10, 2024
·
6 min read
·
Angela Gabriel
Cardiovascular disease
AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug
For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.
October 7, 2024
·
2 min read
·
Tristan Manalac
Approvals
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer
The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.
August 14, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval
AstraZeneca is seeking a fixed-duration approval for Calquence, which will allow patients with chronic lymphocytic leukemia to take breaks from the therapy and prevent excessive toxicities and drug resistance.
July 30, 2024
·
2 min read
·
Tristan Manalac
Adcomms
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm
AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.
July 24, 2024
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo Turn to AI to Explain Phase III NSCLC Miss for Dato-DXd
Using a computational biomarker, the companies say they can identify which patients would derive significant clinical benefit from their experimental antibody-drug conjugate. AstraZeneca and Roche are co-developing and commercializing a companion diagnostic for the biomarker.
September 9, 2024
·
2 min read
·
Tristan Manalac
Drug Development
AstraZeneca’s Imfinzi Fails Phase III NSCLC Trial, Aces Late-Stage Bladder Cancer Study
AstraZeneca’s PD-L1 inhibitor failed to significantly improve disease-free survival in patients with non-small cell lung cancer, but hit its primary endpoint in a late-stage trial in muscle-invasive bladder cancer.
June 25, 2024
·
2 min read
·
Tristan Manalac
Patents
Delaware Judge Throws Out Pfizer’s $107.5M Tagrisso Patent Win Over AstraZeneca
Just months after a jury ordered payment to Pfizer in the patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the lawsuit involving AstraZeneca’s blockbuster lung cancer drug.
August 16, 2024
·
2 min read
·
Tristan Manalac
1 of 60,676
Next
